JPWO2008035757A1 - Jelly-like food containing ubiquinol - Google Patents
Jelly-like food containing ubiquinol Download PDFInfo
- Publication number
- JPWO2008035757A1 JPWO2008035757A1 JP2008535395A JP2008535395A JPWO2008035757A1 JP WO2008035757 A1 JPWO2008035757 A1 JP WO2008035757A1 JP 2008535395 A JP2008535395 A JP 2008535395A JP 2008535395 A JP2008535395 A JP 2008535395A JP WO2008035757 A1 JPWO2008035757 A1 JP WO2008035757A1
- Authority
- JP
- Japan
- Prior art keywords
- ubiquinol
- jelly
- food
- ubiquinone
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 title claims abstract description 131
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 title claims abstract description 87
- 229940040064 ubiquinol Drugs 0.000 title claims abstract description 86
- 235000013305 food Nutrition 0.000 title claims abstract description 83
- 239000003349 gelling agent Substances 0.000 claims abstract description 13
- 229920002472 Starch Polymers 0.000 claims description 22
- 235000019698 starch Nutrition 0.000 claims description 22
- 229920000159 gelatin Polymers 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 20
- 108010010803 Gelatin Proteins 0.000 claims description 18
- 239000008273 gelatin Substances 0.000 claims description 18
- 235000019322 gelatine Nutrition 0.000 claims description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims description 18
- 229920001817 Agar Polymers 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 235000010419 agar Nutrition 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000015110 jellies Nutrition 0.000 claims description 8
- 239000008274 jelly Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 6
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 6
- 229920002752 Konjac Polymers 0.000 claims description 6
- 239000000252 konjac Substances 0.000 claims description 6
- 235000010485 konjac Nutrition 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 240000003183 Manihot esculenta Species 0.000 claims description 5
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- 239000003921 oil Substances 0.000 abstract description 17
- 239000003925 fat Substances 0.000 abstract description 13
- 230000009747 swallowing Effects 0.000 abstract description 10
- 230000002950 deficient Effects 0.000 abstract description 5
- 235000019577 caloric intake Nutrition 0.000 abstract 1
- 235000004213 low-fat Nutrition 0.000 abstract 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 46
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 45
- 235000017471 coenzyme Q10 Nutrition 0.000 description 45
- 229940035936 ubiquinone Drugs 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 239000000203 mixture Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 14
- 235000019634 flavors Nutrition 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- -1 sultiamine Chemical compound 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920002148 Gellan gum Polymers 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000010492 gellan gum Nutrition 0.000 description 4
- 239000000216 gellan gum Substances 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 235000017788 Cydonia oblonga Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000011203 Origanum Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 150000003544 thiamines Chemical class 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JHEPBQHNVNUAFL-AATRIKPKSA-N (e)-hex-1-en-1-ol Chemical compound CCCC\C=C\O JHEPBQHNVNUAFL-AATRIKPKSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MVOSYKNQRRHGKX-UHFFFAOYSA-N 11-Undecanolactone Chemical compound O=C1CCCCCCCCCCO1 MVOSYKNQRRHGKX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CFAKWWQIUFSQFU-UHFFFAOYSA-N 2-hydroxy-3-methylcyclopent-2-en-1-one Chemical compound CC1=C(O)C(=O)CC1 CFAKWWQIUFSQFU-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- MDVYIGJINBYKOM-IBSWDFHHSA-N 3-[(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl]oxypropane-1,2-diol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OCC(O)CO MDVYIGJINBYKOM-IBSWDFHHSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- TWXUTZNBHUWMKJ-UHFFFAOYSA-N Allyl cyclohexylpropionate Chemical compound C=CCOC(=O)CCC1CCCCC1 TWXUTZNBHUWMKJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 108060006004 Ascorbate peroxidase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241001529744 Origanum Species 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- APTGPWJUOYMUCE-UHFFFAOYSA-N S-Ethyl thioacetate Chemical compound CCSC(C)=O APTGPWJUOYMUCE-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000004976 Solanum vernei Nutrition 0.000 description 1
- 241000352057 Solanum vernei Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HKQKYZRQBYBWSZ-BMJUYKDLSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl]disulfanyl]pent-3-enyl] dihydrogen phosphate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCOP(O)(O)=O)/SSC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N HKQKYZRQBYBWSZ-BMJUYKDLSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本発明は、ユビキノールを含有するゼリー状食品に関する。本発明者らは、油脂等に代えてゲル化剤を用いることにより、ユビキノールを安定かつ均一に分散できることを見出し、本発明を完成するに至った。本発明によれば、生体に必要不可欠であるにも関わらず減少・不足しがちなユビキノールを、健常人はもとより高齢者や病人など嚥下能力の低下した人あっても、容易に且つ効率的に補給することが可能となる。また、本発明のゼリー状食品は油脂の含有が低く、エネルギー摂取過多となりがちな現代人にとって、好ましい食品である。The present invention relates to a jelly-like food containing ubiquinol. The present inventors have found that ubiquinol can be dispersed stably and uniformly by using a gelling agent in place of fats and oils, and the present invention has been completed. According to the present invention, ubiquinol, which is indispensable for a living body and tends to be reduced or deficient, can be easily and efficiently applied to a healthy person as well as a person with reduced swallowing ability such as an elderly person or a sick person. It becomes possible to replenish. Further, the jelly-like food of the present invention is a preferred food for modern people who have a low fat content and tend to be excessive in energy intake.
Description
本発明は、日常生活で通常の食品と同様に摂取することにより、生体に必要不可欠なユビキノールを容易に補給することができる、ユビキノールを含有したゼリー状食品及びその用途に関するものである。 The present invention relates to a jelly-like food containing ubiquinol that can be easily replenished with ubiquinol essential for a living body by ingesting it in the same manner as a normal food in daily life, and its use.
ユビキノールは、広く生物界に分布するベンゾキノン誘導体であるユビキノンの2電子還元体である。ユビキノール及びユビキノンは、ミトコンドリア、リソゾーム、ゴルジ体、ミクロソーム、ペルオキシソーム、或いは細胞膜などに局在し、電子伝達系の構成成分としてATP産生賦活、生体内での抗酸化作用、膜安定化に関与している事が知られている生体の機能維持に必要不可欠な物質である。ユビキノンについては、そのビタミン様の機能からビタミンQとも呼ばれており、弱った細胞活性を健康な状態に戻す栄養源として身体を若返らせる成分である。 Ubiquinol is a two-electron reduced form of ubiquinone which is a benzoquinone derivative widely distributed in the living world. Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of electron transport systems. It is an indispensable substance for maintaining the functions of living organisms. Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
生体内でユビキノールとユビキノンはある種の平衡関係にあり、生体内に吸収されたユビキノール/ユビキノンは、相互に酸化/還元される事が知られている。通常、生体内では、ユビキノールとユビキノンの合計重量に対し60〜90%がユビキノールとして存在していると言われている。 It is known that ubiquinol and ubiquinone have a certain equilibrium relationship in the living body, and ubiquinol / ubiquinone absorbed in the living body is mutually oxidized / reduced. Normally, it is said that 60 to 90% of ubiquinol and ubiquinone are present as ubiquinol in vivo.
ユビキノンについては食事によって補給される一方、生体内でも生合成されている事から、正常な状態ではユビキノン及びユビキノールの必要量は充足されているかに見えるが、これらの生体内での含量は加齢や生体が受ける種々のストレスにより顕著に減少することが知られている。 Ubiquinone is supplemented by meals, but it is biosynthesized in vivo, so it seems that the necessary amount of ubiquinone and ubiquinol is satisfied under normal conditions. It is known that it is significantly reduced by various stresses applied to the living body.
例えば、ヒト心臓中ユビキノン含量は、19歳〜21歳の場合110.0μg/gであるのに対し、77歳〜81歳では47.2μg/gと半減することが報告されている(非特許文献1)。また、尿毒症及び慢性の血液透析患者、種々のアレルギー患者の血漿中ユビキノン含量は健常人に比較し減少している(非特許文献2、非特許文献3)。高脂血症患者では、LDLコレステロール画分のユビキノン含量が減少している(非特許文献4)。更に、昨今高コレステロール血漿治療剤として汎用されているコレステロール合成阻害剤の投与が、ユビキノンの生合成をも阻害し、組織でのユビキノン濃度の低下をもたらしていることが指摘されている(非特許文献5)。更に、激しい運動や過労時等、生体内で過酸化物が生成しやすい条件下においても、組織内濃度の減少が推定されている。 For example, the ubiquinone content in the human heart is reported to be halved to 47.2 μg / g in the age of 77 to 81 while it is 110.0 μg / g in the age of 19 to 21 (non-patented). Reference 1). In addition, the ubiquinone content in plasma of uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals (Non-patent Documents 2 and 3). In hyperlipidemia patients, the ubiquinone content of the LDL cholesterol fraction is decreased (Non-patent Document 4). Furthermore, it has been pointed out that administration of a cholesterol synthesis inhibitor, which has been widely used as a therapeutic agent for high cholesterol plasma, has recently inhibited biosynthesis of ubiquinone, resulting in a decrease in ubiquinone concentration in tissues (non-patented). Reference 5). Furthermore, it is estimated that the concentration in the tissue decreases even under conditions where peroxides are likely to be generated in vivo, such as during intense exercise or overwork.
生体内ユビキノール及びユビキノン含量の低下は、その特性上、ATP産生力の減退、心機能の減退、酸化ストレスに対する抵抗性の減退、生体膜の不安定化をもたらし、健康上好ましくない。不足しているユビキノール及びユビキノンを補給することは、ミトコンドリアでのエネルギー産生促進及び生体の抗酸化能を向上し恒常性を維持するために有益である。 A decrease in the ubiquinol and ubiquinone contents in the living body is unfavorable for health because of its characteristics, resulting in decreased ATP productivity, decreased cardiac function, decreased resistance to oxidative stress, and instability of the biological membrane. Supplementing deficient ubiquinol and ubiquinone is beneficial for promoting energy production in mitochondria and improving the antioxidant capacity of the body and maintaining homeostasis.
ユビキノンには、例えば、心疾患、高血圧、肥満、糖尿病、癌、パーキンソン病、歯周病、神経疾患、アレルギー、生殖能、運動能、免疫機能、疲労等の改善や予防の効果が期待されている。 Ubiquinone is expected to improve and prevent heart disease, high blood pressure, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological diseases, allergies, fertility, exercise capacity, immune function, fatigue, etc. Yes.
例えば、ユビキノン投与による心機能の亢進が報告されており(非特許文献6)、ユビキノンによる鬱血性心不全、狭心症、心筋梗塞などの心疾患の改善効果(非特許文献7、非特許文献8)、動脈硬化、高血圧、糖尿病、癌、歯周病、アレルギーなどの予防・改善効果(非特許文献9、非特許文献10、非特許文献11、非特許文献12)、生殖能向上効果、LDLコレステロールの酸化抑制、腎透析患者での透析回数の減少効果、非特異的免疫能の増強効果等が知られている(非特許文献13、非特許文献14)。また、ユビキノンは既に、鬱血性心不全或いは軽度な心疾患による動悸、息切れ、むくみの治療薬として利用されている。 For example, enhancement of cardiac function by ubiquinone administration has been reported (Non-Patent Document 6), and the effect of ubiquinone to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction (Non-Patent Document 7 and Non-Patent Document 8). ), Arteriosclerosis, hypertension, diabetes, cancer, periodontal disease, allergy prevention and improvement effect (Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12), Reproductive performance improvement effect, LDL Antioxidation of cholesterol, an effect of decreasing the number of dialysis in renal dialysis patients, an effect of enhancing nonspecific immunity, and the like are known (Non-patent Documents 13 and 14). Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
日々の生活において低下する生体内ユビキノール及びユビキノン含量を補うためは適度にユビキノールやユビキノンを補給することが必要である。中高年はもとより、若い人でも、過度の運動時に指摘されるような酸化ストレス障害の場合は、特にユビキノール含量が低下するので、ユビキノールを補給して生体の抗酸化能を上げておくことは大切である。生体内のユビキノール含量を向上させるために、外来的にユビキノンを補給する方法が従来より用いられてきた。 In order to compensate for the in vivo ubiquinol and ubiquinone contents that decrease in daily life, it is necessary to appropriately supplement ubiquinol and ubiquinone. Even if you are a middle-aged or younger person, especially in the case of oxidative stress disorder as pointed out during excessive exercise, the content of ubiquinol decreases, so it is important to supplement the body with ubiquinol to increase the antioxidant capacity of the body. is there. In order to improve the ubiquinol content in the living body, a method of replenishing ubiquinone exogenously has been used conventionally.
上記の様に生体の機能維持に必要不可欠で、日々の生活において減少・不足しがちなユビキノンを補給する方法として、錠剤、カプセル剤の形態で医薬として、或いはサプリメントとして補給する方法が既に実施されているが、不足の度合いが軽度で医療の対象とならない健康人、或いは半健康人等にとって、錠剤やカプセル剤として摂取するよりも、通常の食品と同様に摂取する方が簡便である。 As mentioned above, as a method of supplementing ubiquinone, which is indispensable for maintaining the functions of the living body and tends to decrease or lack in daily life, a method of supplementing as a medicine or supplement in the form of tablets or capsules has already been implemented. However, it is easier for a healthy person or a semi-healthy person who has a mild deficiency and is not a medical target to take it in the same way as a normal food, rather than taking it as a tablet or capsule.
この様に、ユビキノンを含有した食品を利用すれば、生体内でユビキノンとユビキノールは平衡関係にあるので、ユビキノンそのものだけでなく不足しがちなユビキノールの補給が容易に可能になると考えられてきた。しかしながら、近年、種々の用途において、ユビキノールを摂取することがユビキノンを摂取することよりも有効であるとの報告がなされている。例えば、ユビキノールがユビキノンよりも経口吸収性に優れていること(特許文献1)や、高コレステロール血症、高脂血症や動脈硬化症の改善・予防に効果があること(特許文献2)が報告されている。また、高齢者や病人ではユビキノンをユビキノールに還元する能力が弱くなるとの報告もある(非特許文献15)。 Thus, it has been considered that if a food containing ubiquinone is used, ubiquinone and ubiquinol are in an equilibrium relationship in the living body, so that not only ubiquinone itself but also ubiquinol which tends to be deficient can be easily supplied. However, in recent years, it has been reported that ingesting ubiquinol is more effective than ingesting ubiquinone in various applications. For example, ubiquinol is superior to ubiquinone in oral absorption (Patent Document 1), and is effective in improving and preventing hypercholesterolemia, hyperlipidemia and arteriosclerosis (Patent Document 2). It has been reported. In addition, there is a report that the ability to reduce ubiquinone to ubiquinol is weak in elderly people and sick people (Non-patent Document 15).
このようにユビキノールを摂取することはその有用性が期待されているが、ユビキノールが非常に酸化されやすいという性質を有していることに加えて、ユビキノールそのままでは吸収性が低く、吸収性を上げるためには油脂等に溶解し、さらに場合によっては界面活性剤なども添加し、酸化を防ぐためにカプセル剤として摂取されるのが一般的である。しかしながらカプセル剤の場合、高齢者や病人など嚥下能力の低い人にとっては摂取しにくいという問題がある。 Ingesting ubiquinol in this way is expected to be useful, but in addition to having the property that ubiquinol is very easily oxidized, ubiquinol itself has low absorbency and increases absorbability. For this purpose, it is generally dissolved in fats and oils, and in some cases, a surfactant or the like is also added and taken as a capsule to prevent oxidation. However, in the case of capsules, there is a problem that it is difficult to take for people with low swallowing ability such as elderly people and sick people.
またユビキノールを含有する食品として、ユビキノールを富化した油脂含有食品(特許文献3)が報告されているが、ここでは、脂溶性物質であるユビキノールを食品に含有させるために、ユビキノールを油脂等に溶解あるいは共存させて使用している。 Moreover, as a food containing ubiquinol, an oil-and-fat-containing food enriched with ubiquinol (Patent Document 3) has been reported. Here, in order to contain ubiquinol, which is a fat-soluble substance, in food, ubiquinol is converted into oil and fat. Dissolved or used together.
上述したように、ユビキノールの摂取においては、従来、油脂や界面活性剤などと同時に摂取する方法が一般的である。油脂(脂肪)は3大栄養素の1種であり、エネルギー源として重要であると同時に、食品に対するなめらかな食感の付与、こくづけ、濃厚感の付与等の機能を持つ。しかし、最近では肥満や生活習慣病への関心の高まりから、食品中の高カロリー物質である脂肪の摂取量を低減化することが求められている。
本発明の目的は、日常生活で通常の食品と同様に摂取することにより、生体に必要不可欠であるにも関わらず、減少・不足しがちなユビキノールを、健常な人はもとより高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く補給することができ、現代人の食生活で問題となっているエネルギー過多に対しても好ましいゼリー状食品及びその用途を提供することにある。 The purpose of the present invention is to take ubiquinol, which is apt to be reduced or deficient by ingesting it in the same way as normal foods in daily life, but not only for healthy people but also for elderly people and sick people, etc. It is an object of the present invention to provide a jelly-like food that can be easily and efficiently replenished even by a person with reduced swallowing ability, and that is preferable for excessive energy, which is a problem in the eating habits of modern people.
本発明者らは、油脂等に代えてゲル化剤を使用してゼリー状とすることにより、ユビキノールを安定かつ均一に分散できてさらに吸収性にも優れたゼリー状食品となりうることをはじめて見出した。そのようなゼリー状食品は、高齢者や病人など嚥下能力の低下した人にとっても有用である。即ち、本発明は以下の通りである。 The present inventors have found for the first time that by using a gelling agent instead of fats and oils, a jelly-like food can be obtained that can stably and uniformly disperse ubiquinol and has excellent absorbability. It was. Such jelly-like foods are also useful for people with reduced swallowing ability such as the elderly and sick. That is, the present invention is as follows.
[1] ユビキノールを含有するゼリー状食品。
[2] ゼリー状とするためのゲル化剤を使用することを特徴とする[1]記載のゼリー状食品。
[3] ゲル化剤として、寒天、ゼラチン、コンニャク粉、ペクチン、片栗でんぷん、葛でんぷん、蕨でんぷん(わらびこ)、タピオカでんぷん及びカラギーナンからなる群より選択される1種以上のゲル化剤を使用することを特徴とする[1]又は[2]のゼリー状食品。
[4] 粘度が5.0×102 〜1.0×105 mPa・s、及び/又は、硬さが5×104 N/m2以下である[1]〜[3]いずれかのゼリー状食品。
[5] さらに有機酸を含有する[1]〜[4]いずれかのゼリー状食品。
[6] さらに抗酸化剤を含有する[1]〜[5]いずれかのゼリー状食品。
[7] さらにビタミン類を含有する[1]〜[6]いずれかのゼリー状食品。
[8] 油脂の含有量が0.5重量%未満である[1]〜[7]いずれかのゼリー状食品。[1] A jelly-like food containing ubiquinol.
[2] The jelly-like food according to [1], wherein a gelling agent for making a jelly is used.
[3] As a gelling agent, one or more gelling agents selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapioca starch and carrageenan are used. The jelly-like food according to [1] or [2], wherein
[4] The jelly-like food according to any one of [1] to [3], wherein the viscosity is 5.0 × 10 2 to 1.0 × 10 5 mPa · s and / or the hardness is 5 × 10 4 N / m 2 or less.
[5] The jelly-like food according to any one of [1] to [4], further containing an organic acid.
[6] The jelly-like food according to any one of [1] to [5], further comprising an antioxidant.
[7] The jelly-like food according to any one of [1] to [6], further containing vitamins.
[8] The jelly-like food according to any one of [1] to [7], wherein the fat content is less than 0.5% by weight.
本発明のゼリー状食品は、日常生活で通常の食品と同様に摂取することにより、生体に必要不可欠であるにも関わらず、減少・不足しがちなユビキノールを、健常な人はもとより高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く補給することができるだけでなく、現代人の食生活で問題となっているエネルギー過多に対しても好ましい低カロリーの食品である。 The jelly-like food of the present invention is ubiquitol that tends to be decreased or deficient by ingesting it in the same way as normal food in daily life. It is a low-calorie food that is not only easily and efficiently replenished by people with reduced swallowing ability, such as sick people, but is also preferred for excess energy, which is a problem in modern diets.
本発明のゼリー状食品は、ユビキノールを含有することを特徴とする。本発明のゼリー状食品において、含有されるユビキノールは、実質的にユビキノール単独であってもよく、又、ユビキノンとユビキノールの混合物であってもよい。本発明において、ユビキノールとユビキノンの混合物を使用する場合、その割合は特に限定されないが、ユビキノールの含有量が高いことが好ましいことから、ユビキノール/ユビキノンの重量比として、40/60以上が好ましく、60/40以上がより好ましく、80/20がさらに好ましく、95/5がよりさらに好ましく、99/1であるのがもっとも好ましい。 The jelly-like food of the present invention is characterized by containing ubiquinol. In the jelly-like food of the present invention, the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol. In the present invention, when a mixture of ubiquinol and ubiquinone is used, the ratio is not particularly limited. However, since the ubiquinol content is preferably high, the weight ratio of ubiquinol / ubiquinone is preferably 40/60 or more. / 40 or more is more preferable, 80/20 is more preferable, 95/5 is still more preferable, and 99/1 is most preferable.
本発明に使用するユビキノールは、合成法もしくは発酵法など、いかなる公知の方法で製造されたものでもよいが、生体に対する安全性を慎重に配慮すれば、肉、魚等の食品に含まれるものと同じ(all-E)−異性体であるのが好ましく、この場合、その製造法が発酵法に由来するものが好ましい。ここで、「発酵法に由来する」とは、好ましい上記立体異性が発酵法に基づき得られることを意味しており、例えば、発酵法により得られた(all-E)−異性体のユビキノン及び/又はユビキノールを、その立体を保持したまま、酸化、還元等の処理により、所望の比率のユビキノールに変換することを妨げない。尚、立体異性体は常法によりHPLCにて分析される。 The ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method, but if it is carefully taken into consideration for safety to living organisms, it is included in foods such as meat and fish. The same (all-E) -isomers are preferred, in which case the production method is derived from the fermentation process. Here, “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, (all-E) -isomer ubiquinone obtained by the fermentation method and It does not prevent the conversion of ubiquinol into a desired ratio of ubiquinol by treatment such as oxidation or reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
また、本発明に使用するユビキノールの製造は、常法で製造されたユビキノン、好ましくは発酵法により製造されたユビキノンを、水素化ほう素ナトリウム、亜ジチオン酸ナトリウム(ハイドロサルファイトナトリウム)、亜鉛等の一般的な還元剤を用いて、常法により還元することにより行うことができる。上記還元後は、晶析やクロマトグラフィーによる濃縮を行っても良い。ユビキノールは、固体状であれ液状であれ、結晶状であれ、アモルファス状であれ使用し得る。 Further, ubiquinol used in the present invention is produced by ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, sodium borohydride, sodium dithionite (hydrosulfite sodium), zinc, etc. It can carry out by reducing by a conventional method using the general reducing agent of. After the reduction, concentration by crystallization or chromatography may be performed. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
ユビキノンとユビキノールの割合は、通常、UV検出器を用いたHPLCシステムにより、試料中のユビキノンとユビキノールを定量し、その量比をもって算出する方法、または、HPLCに電気化学的検出器を組み込んだシステムにより、ユビキノンとユビキノールの割合をピーク面積から算出する方法により求めることができる。電気化学的検出器を組み込んだシステムでは、酸化還元物質を特異的に測れることおよび感度が高いことから、生体あるいは試料に微量に存在するユビキノールの割合を測定する場合は、有用性が高い。具体的には、島津社製のHPLC分析装置に資生堂社製の電気化学的検出器を組み込み、以下のHPLC条件で測定できる。 The ratio of ubiquinone and ubiquinol is usually determined by a method that quantifies ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculates the quantitative ratio thereof, or a system that incorporates an electrochemical detector in HPLC Thus, the ratio of ubiquinone and ubiquinol can be obtained from the peak area. Since a system incorporating an electrochemical detector can specifically measure redox substances and has high sensitivity, it is highly useful when measuring the proportion of ubiquinol present in a minute amount in a living body or sample. Specifically, an electrochemical detector manufactured by Shiseido Co., Ltd. is incorporated into an Shimadzu HPLC analyzer, and measurement can be performed under the following HPLC conditions.
カラム:YMC−Pack(ODS−A303)、検出波長:275nm、移動相:メタノール(88%)、ヘキサン(12%)、流速:1ml/min。 Column: YMC-Pack (ODS-A303), detection wavelength: 275 nm, mobile phase: methanol (88%), hexane (12%), flow rate: 1 ml / min.
本発明のゼリー状食品としては、いわゆるゲル状の形態を有する食品であれば特に限定されないが、具体的には、ゼラチン、寒天、コンニャクなどのゲル化剤によるゼリーやゼリー寄せ、タピオカ、わらびもち、くず、ジャム、煮こごりなどが挙げられる。またこれらゲル状の組成物中に固形物を有しているものであってもかまわない。 The jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form. Specifically, the jelly-like food with gelling agents such as gelatin, agar, konjac, tapioca, warabimochi , Scrap, jam, boiled rice. Moreover, you may have a solid substance in these gel-like compositions.
本発明のゼリー状食品に使用される材料としては、ゲル状の食品原料、または液状の食品原料に適度な粘度を付加したものであれば特に限定されない。例えば、食品として許容できるゲル化剤を使用して、必要であれば、加熱処理や加水などの処理を行い、ゲル状、いわゆるゼリー状にすることによって、本発明のゼリー状食品を製造することができる。 The material used for the jelly-like food of the present invention is not particularly limited as long as an appropriate viscosity is added to a gel-like food material or a liquid food material. For example, by using a gelling agent that is acceptable as a food, if necessary, heat treatment or addition of water is performed to make a gel, so-called jelly, to produce the jelly-like food of the present invention. Can do.
本発明に用いられるゲル化剤としては特に限定されず、とうもろこしでんぷん、片栗でんぷん、馬鈴薯でんぷん、さつまいもでんぷん、葛でんぷん、蕨でんぷん(わらびこ)、タピオカでんぷん、などのでんぷん類、寒天、ゼラチン、コンニャク粉(グルコマンナン、ガラクトマンナン)、ペクチン、カラギーナン、アルギン酸及びその塩、サイリウム、アラビアガム、ローカストビーンガム、グアーガム、タマリンドガム、クインスシードガム、カラヤガム、トラガントガム、ガッティーガム、キサンタンガム、ジェランガム(ネイティブジェランガム、脱アシル型ジェランガム)、タラガム、アラビノガラクタン、ファーセレラン、マルメロ、カードラン、プルラン、デキストラン、カルボキシメチルセルロースナトリウム等のセルロース誘導体等が挙げられる。好ましくは、でんぷん類、寒天、ゼラチン、コンニャク粉、ペクチンである。より好ましくは、寒天、ゼラチン、コンニャク粉、ペクチン、片栗でんぷん、葛でんぷん、蕨でんぷん(わらびこ)、タピオカでんぷんである。これらのゲル化剤は2種以上組み合わせてもかまわない。 The gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, straw starch, tapioca starch, and other starches, agar, gelatin, konjac Flour (glucomannan, galactomannan), pectin, carrageenan, alginic acid and its salts, psyllium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, caraya gum, tragacanth gum, gutty gum, xanthan gum, gellan gum (native gellan gum, Cellulose such as deacylated gellan gum), tara gum, arabinogalactan, fur celerane, quince, curdlan, pullulan, dextran, sodium carboxymethylcellulose Derivatives, and the like. Starches, agar, gelatin, konjac flour and pectin are preferred. More preferred are agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapioca starch. Two or more of these gelling agents may be combined.
本発明のゼリー状食品は、弾性のある半固体の、いわゆるゼリーやゼリー状飲料に類する形状や物性を有しているものであれば特に限定されないが、例えば、その粘度としては、摂取時の温度条件下で、5.0×102 mPa・s以上の粘性を有するのが好ましく、またその上限としては1.0×105 mPa・s以下であるのが好ましい。硬さとしては、6×104 N/m2以下の硬さが好ましく、5×104 N/m2以下であるのがさらに好ましい。The jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to those of so-called jelly and jelly-like beverages, which are elastic semi-solids. It preferably has a viscosity of 5.0 × 10 2 mPa · s or more under temperature conditions, and the upper limit thereof is preferably 1.0 × 10 5 mPa · s or less. The hardness is preferably 6 × 10 4 N / m 2 or less, and more preferably 5 × 10 4 N / m 2 or less.
ここでいう粘度とは、「液体の流れ難さ、あるいは粘っこさの程度を示す物質定数」で、これを粘性率あるいは粘度という。力を加えて流したときに、内部に摩擦を生じて止まっていく、すなわち、押し流す力に抵抗する性質を粘性という。 The viscosity here is “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity refers to the property of resisting the force of squeezing when friction is applied to the inside when it is applied.
ここでいう硬さとは、「一定速度で圧縮したときの抵抗」で、物質に外部から局部的な力(集中荷重)を短時間に加えて、そのときに示される物質の変形度合から変形に対する抵抗の大小を判断してこれを硬さとしている。 The term “hardness” as used herein refers to “resistance when compressed at a constant speed”. A local force (concentrated load) is applied to a substance from the outside in a short period of time, and the degree of deformation of the substance indicated at that time is used for deformation. Judging the magnitude of resistance, this is regarded as hardness.
食品の粘度や硬さは、市販の粘度計(レオメーター、クリープメーター等)を用いて測ることが出来る。 The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
さらに、本発明におけるゼリー状食品は、嚥下障害者向けの食品、栄養補助食品としても使用することができる。高齢社会において、寝たきり・重度の痴呆・脳卒中後遺症等、運動障害のある高齢者数も増加している。嚥下機能が障害されると、食物や飲料を正常に飲み込めず、誤って気管に引き込んでしまう誤嚥(ごえん)によって、窒息死や誤嚥性肺炎の誘発といった危険性もある。健常者では水の様に低粘度の液体がもっとも飲み込み易いが、嚥下困難者においてはとろみのある方がかえって誤嚥を起こしにくいことが知られ、病院、特養ホーム等では液状食品に粘性を加えた食品が用いられている。また、当然食材の硬さも重要であり、ある程度の柔らかさでないと、噛み砕いたり、飲み混んだりすることが難しくなる。 Furthermore, the jelly-like food in the present invention can also be used as a food for dysphagic persons and a dietary supplement. In an aging society, the number of elderly people with movement disorders such as bedridden, severe dementia, and sequelae of stroke is increasing. When the swallowing function is impaired, there is also a risk of death from asphyxia or aspiration pneumonia due to aspiration that cannot be swallowed normally by food or drink, but accidentally withdrawn into the trachea. It is known that low viscosity liquids such as water are most easily swallowed by healthy subjects, but those who have difficulty swallowing are less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important. Unless it is soft to a certain extent, it becomes difficult to chew or mix.
日本厚生労働省では、粘度が1.5×103 mPa・s以上、硬さが1×104 N/m2以下(舌でつぶせる程度の硬さ)のものを、咀嚼・嚥下困難者用食品の基準としていることから、本発明のゼリー状食品を、これら基準を満たすように調整することによって、咀嚼・嚥下困難者用食品として使用することが可能である。また、このようなゼリー状食品は、幼児・老人向け食品用途にも好ましく利用できる。Japan's Ministry of Health, Labor and Welfare has standards for foods for people with difficulty in chewing or swallowing that have a viscosity of 1.5 × 10 3 mPa · s or more and a hardness of 1 × 10 4 N / m 2 or less (hard enough to be crushed by the tongue). Therefore, the jelly-like food of the present invention can be used as a food for persons with difficulty in chewing / swallowing by adjusting to satisfy these criteria. Moreover, such a jelly-like food can be preferably used for food applications for infants and the elderly.
本発明のゼリー状食品において、目的とする粘度や硬度に調整する方法としては特に限定されず、ゲル化剤の種類や使用量を調整したり、適宜その他増粘剤などを使用するなど公知の方法を用いることができる。また、咀嚼・嚥下困難者用食品用途に適した粘度と硬さのゼリー状食品とするためには、例えば、ゲル化剤としてゼラチンと、寒天またはカラギーナンを併用する、あるいは、カラギーナンとキサンタンガムまたはネイティブジェランガムを併用するなどの方法が挙げられる。 In the jelly-like food of the present invention, the method for adjusting to the target viscosity and hardness is not particularly limited, and it is known that the type and amount of the gelling agent are adjusted, and other thickeners are appropriately used. The method can be used. In addition, in order to obtain a jelly-like food having a viscosity and hardness suitable for food use for persons with difficulty in chewing / swallowing, for example, gelatin is used in combination with agar or carrageenan as a gelling agent, or carrageenan and xanthan gum or native The method of using gellan gum together is mentioned.
本発明のゼリー状食品には、抗酸化剤、有機酸、ビタミン類を添加しても良い。 Antioxidants, organic acids, and vitamins may be added to the jelly-like food of the present invention.
抗酸化剤としては、リコペン、カロテノイド類、フラボノイド類、ポリフェノール類、グルタチオン、セレン、チオ硫酸ナトリウム、αリポ酸およびその誘導体、ピクノジェノール、フラバンジェノール、スーパーオキサイドディスムターゼ(SOD)、グルタチオンペルオキシダーゼ、グルタチオン−S−トランスフェラーゼ、グルタチオン還元酵素、カタラーゼ、アスコルビン酸ペルオキシダーゼ、およびこれらの混合物などが挙げられる。これら抗酸化剤はユビキノールの酸化に対する安定性を高め、より安定した高い効果を得る観点から特に好ましい添加物として使用される。 Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, glutathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD), glutathione peroxidase, glutathione- Examples thereof include S-transferase, glutathione reductase, catalase, ascorbate peroxidase, and mixtures thereof. These antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol against oxidation and obtaining a more stable and high effect.
有機酸としては、特に限定はされないが、例えば、クエン酸、クエン酸誘導体、酢酸、乳酸、コハク酸、酒石酸、アスパラギン酸、シュウ酸、リンゴ酸、マロン酸、フマル酸、マレイン酸、プロピオン酸、酪酸、バレリン酸、イソクエン酸、およびこれらの混合物などが挙げられる。有機酸はそれ自体が体に有用な成分であるだけでなく、本発明のゼリー状食品に適度な風味を付加できる点で好ましい。 The organic acid is not particularly limited, for example, citric acid, citric acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, propionic acid, Examples include butyric acid, valeric acid, isocitric acid, and mixtures thereof. The organic acid is not only a component useful for the body itself, but also preferred in that it can add an appropriate flavor to the jelly-like food of the present invention.
ビタミン類としては特に限定されず、例えば、ビタミンA、ビタミンB(ビタミンB1、ビタミンB1誘導体、ビタミンB2、ビタミンB6、ビタミンB12など)、ビタミンC、ビタミンD、ビタミンE、ビタミンK、ビオチン、パントテン酸、ニコチン酸、およびこれらの混合物などが挙げられる。ここで、ビタミンB1誘導体には、チアミンまたはその塩、チアミンジスルフィド、フルスルチアミンまたはその塩、ジセチアミン、ビスブチチアミン、ビスベンチアミン、ベンフォチアミン、チアミンモノフォスフェートジスルフィド、シコチアミン、オクトチアミン、プロスルチアミンなどのビタミンB1としての生理活性を有する化合物のすべてが含まれ得る。 The vitamins are not particularly limited. For example, vitamin A, vitamin B (vitamin B1, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamin E, vitamin K, biotin, pantothene Examples include acids, nicotinic acid, and mixtures thereof. Here, the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbenchamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, octothiamine, pro Any of the compounds having physiological activity as vitamin B1, such as sultiamine, can be included.
これらの抗酸化物質、有機酸、ビタミン類は、2種類以上を組み合わせても良い。 These antioxidants, organic acids, and vitamins may be used in combination of two or more.
本発明のゼリー状食品に含まれる他の成分としては、食品に使用できる成分であれば特に限定されず、必要に応じて、糖類、甘味料、果汁、フレーバー粉末、香料、防腐剤、着色剤や保存剤などが使用できる。 The other components contained in the jelly-like food of the present invention are not particularly limited as long as they are components that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, fragrances, preservatives, and coloring agents. And preservatives can be used.
糖類としては特に限定されず、例えば、庶糖、ブドウ糖、果糖、乳糖、麦芽糖、異性化糖、カップリングシュガー、パラチノース、ネオシュガー、還元澱粉糖化飴、キシロース、ソルボース、ラクツロース、ポリデキストロース等の水溶性糖類、およびこれらの混合物などが挙げられる。 The sugar is not particularly limited, and for example, water-soluble sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, polydextrose, etc. Examples thereof include saccharides and mixtures thereof.
甘味料としては特に限定されず、例えば、サッカリンナトリウム、アスパルテーム、ステビオサイド、ステビアエキス、パラメトキシシンナミックアルデヒド、ネオヘスペリジルジヒドロカルコン、ペリラルチン、およびこれらの混合物などが挙げられる。 The sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
果汁としては特に限定されず、例えば、りんご果汁、オレンジ果汁、ぶどう果汁、メロン果汁、レモン果汁などが用いられる。 The fruit juice is not particularly limited, and for example, apple juice, orange juice, grape juice, melon juice, lemon juice and the like are used.
フレーバー粉末としては特に限定されず、例えば、コーヒー粉末、抹茶粉末、煎茶粉末、ココア粉末などが用いられる。 The flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
香料としては特に限定されず、例えば、メントール、カルボン、アネトール、シネオール、サリチル酸メチル、シンナミックアルデヒド、オイゲノール、3−(1−メントキシ)プロパン−1,2−ジオール、チモール、リナロール、リナリールアセテート、リモネン、メントン、メンチルアセテート、N−置換−パラメンタン−3−カルボキサミド、ピネン、オクチルアルデヒド、シトラール、プレゴン、カルビールアセテート、アニスアルデヒド、エチルアセテート、エチルブチレート、アリルシクロヘキサンプロピオネート、メチルアンスラニレート、エチルメチルエチニルグリシデート、バニリン、ウンデカラクトン、ヘキサナール、エチルアルコール、プロピルアルコール、ブタノール、イソアミルアルコール、ヘキセノール、ジメチルサルファイド、シクロテン、フルフラール、トリメチルピラゾン、エチルラクテート、エチルチオアセテートなどの単品香料、更に、ペパーミント油、スペアミント油、アニス油、ユーカリ油、ウインターグリーン油、カシア油、クローブ油、タイム油、セージ油、レモン油、オレンジ油、ハッカ油、カルダモン油、コリアンダー油、マンダリン油、ライム油、ラベンダー油、ローズマリー油、ローレル油、カモミール油、キャラウェイ油、マジョラム油、ベイ油、レモングラス油、オリガナム油、パインニードル油、ネロリ油、ローズ油、ジャスミン油、イリスコンクリート、アブソリュートペパーミント、アブソリュートローズ、オレンジフラワーなどの天然香料、ストロベリーフレーバー、アップルフレーバー、バナナフレーバー、パイナップルフレーバー、グレープフレーバー、マンゴーフレーバー、バターフレーバー、ミルクフレーバー、フルーツミックスフレーバー、トロピカルフルーツフレーバーなどの調合香料、およびこれらの混合物などが挙げられる。 The fragrance is not particularly limited, and examples thereof include menthol, carvone, anethole, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3- (1-menthoxy) propane-1,2-diol, thymol, linalool, linalyl acetate, Limonene, menthone, menthyl acetate, N-substituted-paramentane-3-carboxamide, pinene, octyl aldehyde, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate, allylcyclohexane propionate, methyl anthranilate , Ethyl methyl ethynyl glycidate, vanillin, undecalactone, hexanal, ethyl alcohol, propyl alcohol, butanol, isoamyl alcohol, hexenol, di Single flavors such as tilsulfide, cycloten, furfural, trimethylpyrazone, ethyl lactate, ethylthioacetate, peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil, cassia oil, clove oil, thyme oil, sage Oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, lime oil, lavender oil, rosemary oil, laurel oil, chamomile oil, caraway oil, marjoram oil, bay oil, lemongrass oil, Natural flavors such as origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, Iris concrete, absolute peppermint, absolute rose, orange flower, strawberry flavor, apple flavor, banana flavor , Pineapple flavor, grape flavor, mango flavor, butter flavor, milk flavor, fruit mix flavors, blended fragrance, such as tropical fruit flavors, and mixtures thereof, and the like.
防腐剤としては特に限定されず、例えば、アミノエチルスルホン酸、安息香酸、安息香酸ナトリウム、エタノール、エデト酸ナトリウム、カンテン、dl−カンフル、クエン酸、クエン酸ナトリウム、サリチル酸、サリチル酸ナトリウム、サリチル酸フェニル、ジブチルヒドロキシトルエン、ソルビン酸、ソルビン酸カリウム、窒素、デヒドロ酢酸、デヒドロ酢酸ナトリウム、2−ナフトール、白糖、ハチミツ、パラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、l−メントール、ユーカリ油、およびこれらの混合物などが挙げられる。 The preservative is not particularly limited, for example, aminoethyl sulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citric acid, sodium citrate, salicylic acid, sodium salicylate, phenyl salicylate, Dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, paraoxybenzoate Examples include propyl acid, methyl paraoxybenzoate, l-menthol, eucalyptus oil, and mixtures thereof.
着色剤としては特に限定されず、食品に添加することが許可されているものなどを使用することができ、例えば、青色1号、黄色4号、緑色3号、赤色5号、レーキ色素、二酸化チタン、赤キャベツ色素、紅麹色素、ムラサキイモ色素、クチナシ色素、コチニール色素、カラメル色素、クロロフィル、およびこれらの混合物などが挙げられる。 The colorant is not particularly limited, and those permitted to be added to foods can be used. For example, blue No. 1, yellow No. 4, green No. 3, red No. 5, lake dye, dioxide Examples thereof include titanium, red cabbage pigment, sockeye pigment, purple potato pigment, gardenia pigment, cochineal pigment, caramel pigment, chlorophyll, and mixtures thereof.
保存剤としては特に限定されず、例えば、安息香酸、安息香酸ナトリウム、エタノール、エデト酸ナトリウム、乾燥亜硫酸ナトリウム、クエン酸、グリセリン、サリチル酸、サリチル酸ナトリウム、ジブチルヒドロキシトルエン、D−ソルビトール、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸ナトリウム、パラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、プロピレングリコール、リン酸、およびこれらの混合物などが挙げられる。 The preservative is not particularly limited. For example, benzoic acid, sodium benzoate, ethanol, sodium edetate, dry sodium sulfite, citric acid, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D-sorbitol, sorbic acid, sorbine Examples include potassium acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, propylene glycol, phosphoric acid, and mixtures thereof. It is done.
また、本発明のゼリー状食品には、若干量の油脂成分を含んでいてもかまわないが、カロリーを低く抑えるという目的の場合はその使用量は少ないほど好ましく、その観点からは油脂の使用量は、食品全体量に対し10重量%以下であるのが好ましく、5重量%以下であるのがより好ましく、1重量%以下であるのがさらに好ましく、0.5重量%未満であるのが特に好ましい。通常、一般食品やサプリメントにおいて、ユビキノールを製剤や食品中に可溶化あるいは分散させるために、ユビキノールよりも大過剰量の油脂が使用されるが、本発明のゼリー状食品においては、ゼリー状とすることで好適にユビキノールを食品中分散させることが可能なため、食品中のユビキノールに対する油脂の含有量を例えば等量以下、さらには半分以下とすることもでき、油脂を実質的にあるいはまったく含まないことも可能である。 In addition, the jelly-like food of the present invention may contain a small amount of fat and oil components, but for the purpose of keeping calories low, the amount used is preferably as small as possible. Is preferably 10% by weight or less, more preferably 5% by weight or less, still more preferably 1% by weight or less, and particularly preferably less than 0.5% by weight based on the total amount of food. preferable. Usually, in general foods and supplements, a large excess of oil and fat is used than ubiquinol in order to solubilize or disperse ubiquinol in preparations and foods, but in the jelly-like food of the present invention, it is jelly-like. Therefore, it is possible to suitably disperse ubiquinol in foods, so that the content of fats and oils relative to ubiquinol in foods can be, for example, equal or less, and even less than half, and substantially or not contain fats and oils. It is also possible.
本発明のゼリー状食品は、一般食品として、また栄養補助食品、健康食品として、健常者のみならず、高齢者や何らかの疾患を有している病人に、ユビキノールを補給しうる低カロリー食品として摂取できる。さらには、また、嚥下障害を有する高齢者や病人に対する補助食品としても有用である。さらには、従来のカプセル摂取が困難であったペットなどの動物への応用も可能である。その形態としては、例えばカップ等に装填されたゼリーとして、あるいはパウチ等に充填されたゼリー状飲料として提供される他、使用者側で加水及び/又は加熱などの調理を行うことで、ゼリー状とすることができる粉末・固形形態として提供される。 The jelly-like food of the present invention is ingested as a low-calorie food that can be supplemented with ubiquinol not only for healthy people but also for elderly people and sick people who have some disease, as general foods, as dietary supplements, and health foods. it can. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can be applied to animals such as pets, which have been difficult to ingest in conventional capsules. As its form, for example, it is provided as a jelly loaded in a cup or the like, or as a jelly-like beverage filled in a pouch or the like, and by performing cooking such as hydration and / or heating on the user side, It is provided as a powder / solid form.
本発明のゼリー状食品の摂取量としては特に限定されないが、成人1日あたり、ユビキノール量として1mg〜1000mg、好ましくは10mg〜500mg、さらに好ましくは30mg〜300mgである。 The intake amount of the jelly-like food of the present invention is not particularly limited, but it is 1 mg to 1000 mg, preferably 10 mg to 500 mg, more preferably 30 mg to 300 mg as the amount of ubiquinol per day for an adult.
以下に実施例を揚げて本発明を更に詳しく説明するが、本発明はこれら実施例のみに限定されるものではない。尚、純度及びユビキノール/ユビキノンの比率(重量比)は上記HPLC分析により求めた。 Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples. The purity and the ubiquinol / ubiquinone ratio (weight ratio) were determined by the HPLC analysis.
(製造例1)ユビキノールの製造
1000gのエタノール中に、100gのユビキノン(純度99.4%)、60gのL−アスコルビン酸を加え、78℃にて攪拌し、還元反応を行った。30時間後、50℃まで冷却し、同温を保持しながらエタノール330gと水70gを添加した。このエタノール溶液(ユビキノール100gを含む)を攪拌しながら、10℃/時間の冷却速度で2℃まで冷却し、白色のスラリーを得た。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水、冷エタノールで順に洗浄(洗浄に用いた冷溶媒の温度は2℃)して、さらに湿結晶を減圧乾燥(20〜40℃、1〜30mmHg)することにより、白色の乾燥結晶97gを得た。減圧乾燥を除く全ての操作は窒素雰囲気下で実施した。 Production Example 1 Production of Ubiquinol 100 g of ubiquinone (purity 99.4%) and 60 g of L-ascorbic acid were added to 1000 g of ethanol, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C., and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing 100 g of ubiquinol), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry. The obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C.), and the wet crystals were further dried under reduced pressure (20 to 40 ° C., 1 to 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
(製造例2)ユビキノールの製造
100gのユビキノン(純度99.4%)を25℃で1000gのヘプタン溶液に溶解させた。攪拌しながら、還元剤として次亜硫酸ナトリウム(純度75%以上)100gに1000mlの水を加えて溶解させた水溶液を徐々に添加し、25℃、pH4〜6で還元反応を行った。2時間後、反応液から水相を除去し、脱気した飽和食塩水1000gでヘプタン相を6回水洗した。以上、すべての操作は窒素雰囲気下で実施した。このヘプタン相を減圧下にて溶媒置換し、50℃のユビキノールの7%(w/w)エタノール溶液を調製した(ユビキノールを100g含む)。このエタノール溶液に水50gを添加し、攪拌しながら、10℃/時間の冷却速度で2℃まで冷却して結晶を析出させた。全ての操作は窒素雰囲気下で実施した。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水、冷エタノールで順に洗浄(洗浄に用いた冷溶媒の温度は2℃)して、さらに、湿結晶を減圧乾燥(20〜40℃、1〜30mmHg)することにより、白色の乾燥結晶97gを得た。 Production Example 2 Production of Ubiquinol 100 g of ubiquinone (purity 99.4%) was dissolved in 1000 g of heptane solution at 25 ° C. While stirring, an aqueous solution prepared by adding 1000 ml of water to 100 g of sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added, and a reduction reaction was performed at 25 ° C. and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with 1000 g of degassed saturated brine. As described above, all operations were performed in a nitrogen atmosphere. The heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C. (containing 100 g of ubiquinol). 50 g of water was added to this ethanol solution, and the mixture was cooled to 2 ° C. at a cooling rate of 10 ° C./hour with stirring to precipitate crystals. All operations were performed under a nitrogen atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C.), and the wet crystals were further dried under reduced pressure (20 to 40 ° C. 1 to 30 mmHg) to obtain 97 g of white dry crystals.
(実施例1)ゼリー状食品の製造
400gの水にゼラチン(新田ゼラチン株式会社製;タイプR)20gを加え、70℃にてゼラチンを溶解させた。同温を維持しながら、製造例1で得られた5gのユビキノールを加え、ユビキノールが完全に融解した後、TKホモミキサーMarkII2.5型(プライミクス株式会社製)を用い、5分間(10000rpm)乳化させた。この乳化液を室温まで冷却させた後、さらに、冷蔵庫(4℃)にて2時間冷却することにより、ユビキノールを含有するゼリーを調製した。得られたゼリーは均一で、ゼリー中ユビキノールが析出することなく良好に分散していた。 (Example 1) Production of jelly-like food 20 g of gelatin (Nitta Gelatin Co., Ltd .; type R) was added to 400 g of water, and gelatin was dissolved at 70 ° C. While maintaining the same temperature, 5 g of ubiquinol obtained in Production Example 1 was added, and ubiquinol was completely melted, and then emulsified for 5 minutes (10000 rpm) using TK homomixer Mark II2.5 (manufactured by Primix Co., Ltd.). I let you. The emulsion was cooled to room temperature, and further cooled in a refrigerator (4 ° C.) for 2 hours to prepare a jelly containing ubiquinol. The obtained jelly was uniform and was well dispersed without precipitation of ubiquinol in the jelly.
(実施例2)吸収性評価
<サンプル調製>
動物試験のため、ユビキノールを含有するゼリー状食品を乾燥させたモデルサンプルを以下のようにして調製した。 Example 2 Absorbability Evaluation <Sample Preparation>
For animal testing, a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
160gの蒸留水に、ゼラチン(新田ゼラチン株式会社製;APH−250)40gを60℃で溶解させ、ゼラチン水溶液を作成した。この水溶液を60℃に加温後、上記製造例1で得られたユビキノール粉末6.2gを添加して溶融させた後、TKホモミキサーMarkII(プライミクス株式会社製)で10000回転×5分間乳化し、水中油型乳化組成物を得た。ここで得た水中油型乳化組成物75gを、あらかじめ90℃に加熱しておいた、MCT(理研ビタミン社製;アクターM−2)145gおよび界面活性剤(ポリグリセリン縮合リシノール酸エステル:阪本薬品工業株式会社製;SYグリスターCRS−75)5gからなる油性成分に添加し、攪拌及び懸濁液の温度を105℃に調整することで、水分を蒸発させた。その後は、常法に従って、固液分離により油性成分をろ別し、約500gのエタノールで粒子に付着した油性成分を洗浄・除去後、50℃で乾燥して、ユビキノールがゼラチン中に分散した粒子状組成物(ゼリー状食品のモデルサンプル)を得た。この組成物および製造例1のユビキノール結晶(粉末そのまま)を、それぞれラット用カプセルに詰めて評価サンプルとした。 In 160 g of distilled water, 40 g of gelatin (manufactured by Nitta Gelatin Co., Ltd .; APH-250) was dissolved at 60 ° C. to prepare an aqueous gelatin solution. After heating this aqueous solution to 60 ° C., 6.2 g of the ubiquinol powder obtained in Production Example 1 above was added and melted, and then emulsified with TK homomixer Mark II (manufactured by Primics Co., Ltd.) for 10,000 rotations × 5 minutes. An oil-in-water emulsion composition was obtained. 145 g of MCT (manufactured by Riken Vitamin Co., Ltd .; Actor M-2) and surfactant (polyglycerin condensed ricinoleic acid ester: Sakamoto Yakuhin Co., Ltd.) heated in advance to 90 ° C., 75 g of the oil-in-water emulsion composition obtained here. Kogyo Co., Ltd .; SY Glister CRS-75) was added to an oily component consisting of 5 g, and the water was evaporated by adjusting the temperature of the stirring and suspension to 105 ° C. Thereafter, according to a conventional method, oily components are separated by solid-liquid separation, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C., and particles in which ubiquinol is dispersed in gelatin. -Like composition (model sample of jelly-like food) was obtained. The composition and the ubiquinol crystals of Production Example 1 (powder as they were) were packed in rat capsules to give evaluation samples.
<実験系>
8週齢の雄性Sprague−Dawleyラット(ブリーダーまたは入手元:日本エスエルシー株式会社)に上記に記載の被験物質をユビキノールとして10mg/kgの用量で、カプセル用ゾンデを用いて経口投与した(各サンプルN=5)。被験物質投与1、2、4、8、および24時間後に各ラットより血液を採取した。採取した血液を遠心分離し、血漿を得た。その後、血漿中のユビキノールの酸化処理、およびユビキノンの抽出処理を行い、HPLCを用いてユビキノンの濃度を測定した。<Experimental system>
8-week-old male Sprague-Dawley rats (bleeder or source: Nippon SLC Co., Ltd.) were orally administered using a capsule sonde at a dose of 10 mg / kg as the test substance described above as ubiquinol (each sample). N = 5). Blood was collected from each rat 1, 2, 4, 8, and 24 hours after administration of the test substance. The collected blood was centrifuged to obtain plasma. Thereafter, oxidation treatment of ubiquinol in plasma and extraction treatment of ubiquinone were performed, and the concentration of ubiquinone was measured using HPLC.
以下に、ユビキノールバルク、またはユビキノールとゼラチンを含む組成物(被験物質)を経口投与した後の血漿中ユビキノン最高血中濃度(Cmax)と被験物質投与24時間後までの血漿中ユビキノン濃度の経時変化曲線下面積(AUC)値を示す。 The following changes in plasma ubiquinone peak blood concentration (Cmax) after oral administration of a ubiquinol bulk or a composition (test substance) containing ubiquinol and gelatin, and changes in plasma ubiquinone concentration over time up to 24 hours after administration of the test substance The area under the curve (AUC) value is shown.
ユビキノール結晶と、ゼラチン中にユビキノールが分散した組成物の経口投与後の血漿中ユビキノン濃度を比較すると、ゼラチン中にユビキノールが分散した組成物の方が高い血漿中濃度を示し、また、AUCも高いことが示された。すなわち、ゼラチン中にユビキノールを共存させると吸収性が向上することが明らかとなった。 Comparing the ubiquinol crystals and the composition of ubiquinol dispersed in gelatin after oral administration, the plasma concentration of ubiquinol dispersed in gelatin showed higher plasma concentration and higher AUC. It was shown that. That is, it has been clarified that the absorption is improved when ubiquinol is allowed to coexist in gelatin.
(調製例1)ゼリー状食品
ゼラチンに加水・加熱を行って溶解させた後、製造例1で得たユビキノールを加えてホモジナイズし、ユビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼイン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸Ca、クエン酸、香料、クエン酸Na、ビタミン類を加えて、十分攪拌しながらカップ状容器に充填することによって、ユビキノールを含有したゼリー状食品を得た。得られたゼリー状食品の味は良好であった。 (Preparation Example 1) Jelly-like food gelatin was dissolved by heating and heating, and then ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble product (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, lactic acid Ca, citric acid, fragrance, sodium citrate, vitamins, and stir well into a cup-shaped container. By filling, a jelly-like food containing ubiquinol was obtained. The taste of the obtained jelly-like food was good.
(調製例2)ゼリー状食品
ゼラチンに加水・加熱を行って溶解させた後、製造例1で得たユビキノールを加えてホモジナイズし、ユビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼイン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸Ca、クエン酸、香料、クエン酸Na、ビタミン類を加えて、十分攪拌しながらアルミ複合シートから形成されたパウチに充填密封することによって、ユビキノールを含有したゼリー状食品を得た。得られたゼリー状食品の味は良好であった。 (Preparation Example 2) The gelatinous food gelatin was dissolved by heating and heating, and then ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, lactic acid Ca, citric acid, fragrance, sodium citrate, vitamins, and from the aluminum composite sheet with sufficient stirring A jelly-like food containing ubiquinol was obtained by filling and sealing the formed pouch. The taste of the obtained jelly-like food was good.
Claims (8)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006257240 | 2006-09-22 | ||
JP2006257240 | 2006-09-22 | ||
PCT/JP2007/068350 WO2008035757A1 (en) | 2006-09-22 | 2007-09-21 | Jelly-like food containing ubiquinol |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2008035757A1 true JPWO2008035757A1 (en) | 2010-01-28 |
Family
ID=39200580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008535395A Pending JPWO2008035757A1 (en) | 2006-09-22 | 2007-09-21 | Jelly-like food containing ubiquinol |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008035757A1 (en) |
WO (1) | WO2008035757A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009041449A1 (en) * | 2007-09-25 | 2009-04-02 | Kaneka Corporation | Antiobesity agent |
GB2494475A (en) * | 2011-09-12 | 2013-03-13 | Works With Water Nutraceuticals Ltd | A nutraceutical supplement and method of making |
JP5869856B2 (en) * | 2011-11-30 | 2016-02-24 | キユーピー株式会社 | Liquid seasoning containing daikon radish in a container |
TW201336428A (en) * | 2012-03-05 | 2013-09-16 | Terumo Corp | Semi-solidified nutritive agent |
JP6459206B2 (en) * | 2014-04-25 | 2019-01-30 | ユーハ味覚糖株式会社 | Superabsorbent ubiquinol formulation |
US9757332B2 (en) | 2013-05-20 | 2017-09-12 | Uha Mikakuto Co., Ltd. | Gel-like composition having high ubiquinol content |
JP6146129B2 (en) * | 2013-05-20 | 2017-06-14 | ユーハ味覚糖株式会社 | Method for producing reduced coenzyme Q10-containing gummy candy |
JP6398181B2 (en) * | 2013-11-29 | 2018-10-03 | ユーハ味覚糖株式会社 | Ubiquinol-rich gel composition |
JP6147132B2 (en) * | 2013-08-01 | 2017-06-14 | 江崎グリコ株式会社 | Frozen jelly |
JP6287123B2 (en) * | 2013-11-29 | 2018-03-07 | ユーハ味覚糖株式会社 | Ubiquinol-containing liquid composition |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01206960A (en) * | 1988-02-16 | 1989-08-21 | Takenori Kato | Gelatinous substance |
JPH03224452A (en) * | 1990-01-31 | 1991-10-03 | Kyokuto Internatl Corp | Chestnut-like food |
JPH0630714A (en) * | 1992-07-20 | 1994-02-08 | Meiji Seika Kaisha Ltd | Preparation of jelly dough |
JP2002218917A (en) * | 2001-01-23 | 2002-08-06 | Sanei Gen Ffi Inc | Gel composition comprising dispersed insoluble solid material and application thereof |
JP2002255846A (en) * | 2001-02-26 | 2002-09-11 | Sunstar Inc | Oral composition |
JP2003504479A (en) * | 1999-07-12 | 2003-02-04 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | Preparations without crosslinker |
JP2004173678A (en) * | 2002-09-30 | 2004-06-24 | Morinaga & Co Ltd | Low water-releasing gel-like composition and method for producing the same |
JP2005143380A (en) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | Nutritional food using snapping turtle egg |
JP2005143365A (en) * | 2003-11-13 | 2005-06-09 | Toshihiro Nomura | Food formulated with fat-soluble effective component |
WO2005097091A1 (en) * | 2004-04-09 | 2005-10-20 | Kaneka Corporation | Composition comprising reduced-form coenzyme q10 and carotenoid compound |
JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
JP2006022064A (en) * | 2004-07-09 | 2006-01-26 | Asahi Kasei Pharma Kk | Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic |
JP2006070016A (en) * | 2004-08-02 | 2006-03-16 | Kaneka Corp | Whitening composition containing reduced coenzyme q |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200302055A (en) * | 2002-01-18 | 2003-08-01 | Kaneka Corp | Ubiquinol-enriched fat-containing foods |
-
2007
- 2007-09-21 WO PCT/JP2007/068350 patent/WO2008035757A1/en active Application Filing
- 2007-09-21 JP JP2008535395A patent/JPWO2008035757A1/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01206960A (en) * | 1988-02-16 | 1989-08-21 | Takenori Kato | Gelatinous substance |
JPH03224452A (en) * | 1990-01-31 | 1991-10-03 | Kyokuto Internatl Corp | Chestnut-like food |
JPH0630714A (en) * | 1992-07-20 | 1994-02-08 | Meiji Seika Kaisha Ltd | Preparation of jelly dough |
JP2003504479A (en) * | 1999-07-12 | 2003-02-04 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | Preparations without crosslinker |
JP2002218917A (en) * | 2001-01-23 | 2002-08-06 | Sanei Gen Ffi Inc | Gel composition comprising dispersed insoluble solid material and application thereof |
JP2002255846A (en) * | 2001-02-26 | 2002-09-11 | Sunstar Inc | Oral composition |
JP2004173678A (en) * | 2002-09-30 | 2004-06-24 | Morinaga & Co Ltd | Low water-releasing gel-like composition and method for producing the same |
JP2005143365A (en) * | 2003-11-13 | 2005-06-09 | Toshihiro Nomura | Food formulated with fat-soluble effective component |
JP2005143380A (en) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | Nutritional food using snapping turtle egg |
WO2005097091A1 (en) * | 2004-04-09 | 2005-10-20 | Kaneka Corporation | Composition comprising reduced-form coenzyme q10 and carotenoid compound |
JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
JP2006022064A (en) * | 2004-07-09 | 2006-01-26 | Asahi Kasei Pharma Kk | Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic |
JP2006070016A (en) * | 2004-08-02 | 2006-03-16 | Kaneka Corp | Whitening composition containing reduced coenzyme q |
Also Published As
Publication number | Publication date |
---|---|
WO2008035757A1 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2008035757A1 (en) | Jelly-like food containing ubiquinol | |
JP6745250B2 (en) | Moringa extract | |
JP5147239B2 (en) | Coenzyme Q10-containing emulsion composition | |
EP1755683A2 (en) | Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof | |
JP5705898B2 (en) | Liver function improving agent | |
EP1897539B1 (en) | Anti-fatigue composition | |
WO2006112283A1 (en) | Anti-fatigue agent | |
JPWO2007013556A1 (en) | Cancer prevention composition | |
WO2006003909A1 (en) | Fat combustion accelerator | |
JP2001072583A (en) | Prophylactic or therapeutic composition for hyperlipemia | |
JP6443804B2 (en) | Natural killer cell activity promoter | |
JP2007254427A (en) | Antioxidant and its use | |
JP2007254427A5 (en) | ||
US20090246185A1 (en) | Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent | |
JP7044306B2 (en) | Leucine blood concentration increase promoter and its uses | |
JP2015189693A (en) | Sirt1 activator and use of the sirt1 activator | |
JP2013192514A (en) | Method for manufacturing oyster extract | |
JP6369830B2 (en) | Immune cell proliferation promoter | |
JP7445689B2 (en) | lipolysis accelerator | |
JP2012206964A (en) | PPAR-α ACTIVITY REGULATING AGENT | |
JP4942354B2 (en) | Reduced coenzyme Q water-soluble composition | |
JP4939822B2 (en) | LDL oxidation resistance improver | |
JP4089874B2 (en) | Coenzyme Q10-containing beverage | |
JP2022062711A (en) | Antioxidative composition | |
JP2022038319A (en) | Interferon-γ production promoter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120918 |